Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 3/20 | 0.50 |
| ▸ | PYGL | P06737 | 3/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.47 |
| ▸ | TRPV1 | Q8NER1 | 4/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | FPR2 | P25090 | 1/20 | 0.38 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.37 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.37 |
| ▸ | GPR132 | Q9UNW8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25549285 | 1.00 | CXCR2 (0.50) | CXCR2PYGLCYP2C9TRPV1MAOA | |
| SCHEMBL25205658 | 1.00 | CXCR2 (0.50) | CXCR2PYGLCYP2C9TRPV1MAOA | |
| SCHEMBL25548916 | 0.91 | PYGL (0.44) | CXCR2PYGLCYP2C9TRPV1MAOA | |
| SCHEMBL25549288 | 0.91 | PYGL (0.44) | CXCR2PYGLCYP2C9TRPV1MAOA | |
| SCHEMBL25201145 | 0.91 | PYGL (0.44) | CXCR2PYGLCYP2C9TRPV1MAOA | |
| SCHEMBL25549096 | 0.91 | CXCR2 (0.49) | CXCR2PYGLCYP2C9TRPV1 | |
| SCHEMBL23460775 | 0.90 | CXCR2 (0.63) | CXCR2PYGLCYP2C9MAOAMRGPRX4 | |
| SCHEMBL23460776 | 0.90 | CXCR2 (0.63) | CXCR2PYGLCYP2C9MAOAMRGPRX4 | |
| SCHEMBL25549099 | 0.90 | CXCR2 (0.63) | CXCR2PYGLCYP2C9MAOAMRGPRX4 | |
| SCHEMBL23461898 | 0.87 | CXCR2 (0.48) | CXCR2TRPV1FPR2MRGPRX4PTGER4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159438-A1 | ARYLAMIDES AND METHODS OF USE THEREOF | GENZYME CORPORATION | 2023-05-25 | — | — | US | disclosed |
| US-20230159438-A1 | ARYLAMIDES AND METHODS OF USE THEREOF | GENZYME CORPORATION | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159438-A1 | ARYLAMIDES AND METHODS OF USE THEREOF | CFTR, AADAC, ARSA | CXCR2 1205/4885PYGL 1117/4885CYP2C9 500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.